Verve won trial success with a gene-editing milestone. Why don't investors like it? - Endpoints News
endpts.comSubmitted by endpointsnews6292 in health
This weekend, Verve Therapeutics presented the first-ever results of an in vivo base editing therapy in humans, marking a major milestone not only for the company but also for the gene editing field as a whole. But on Monday morning, the biotech’s stock tumbl…